# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Yasmeen Rahimi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight and maintains $270 ...
Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phas...
Needham analyst Ami Fadia initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Pric...
Guggenheim analyst Yatin Suneja initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announce...